OTCMKTS:TKPYY - Takeda Pharmaceutical Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $21.0250 -0.14 (-0.66 %) (As of 07/20/2018 04:00 PM ET)Previous Close$21.1650Today's Range$20.79 - $21.1052-Week Range$18.93 - $31.29Volume413,613 shsAverage Volume469,951 shsMarket Capitalization$32.58 billionP/E Ratio20.85Dividend Yield2.89%Beta0.47 Company ProfileAnalyst RatingsEarnings HistoryHeadlinesSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Takeda Pharmaceutical Company Limited engages in the research and development, manufacture, marketing, and sale of pharmaceutical products worldwide. The company operates in three segments: Prescription Drug, Consumer Healthcare, and Other. It offers prescription, OTC, and quasi-drugs; and reagents in various therapeutic areas, including oncology, gastroenterology, central nervous system (CNS), vaccines, and others. The company is also involved in clinical diagnostics, chemical products, and other businesses. Takeda Pharmaceutical Company Limited has a research collaboration with Shattuck Labs, Inc. to explore and develop checkpoint fusion proteins that have the potential to become immunotherapies; and a collaboration alliance with Stanford University. It also has collaboration agreements with Samsung Bioepis Co., Ltd. to jointly fund and co-develop various novel biologic therapies in unmet disease areas; AstraZeneca PLC to develop and commercialize MEDI1341, an alpha synuclein antibody for the treatment of Parkinson's disease; Noile-Immune Biotech Inc. for the research and development of cancer immunotherapy; HitGen Ltd for the DNA-encoded library based drug discovery research; Montreal Neurological Institute to discover and develop treatments for amyotrophic lateral sclerosis; Denali Therapeutics to develop and commercialize therapeutic product candidates for neurodegenerative diseases; Fujifilm to develop regenerative medicine product for heart patients; and Wave Life Sciences Ltd. to discover, develop, and commercialize nucleic acid therapies for disorders of CNS, as well as Drugs for Neglected Diseases initiative. In addition, the company has a licensing agreement with Fimecs, Inc. for the development of novel immuno-oncology therapies; and a clinical collaboration with Nektar Therapeutics to evaluate the combination of NKTR-214 and TAK-659. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Osaka, Japan. Receive TKPYY News and Ratings via Email Sign-up to receive the latest news and ratings for TKPYY and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolOTCMKTS:TKPYY CUSIPN/A Webwww.takeda.com Phone816-6204-2111 Debt Debt-to-Equity Ratio0.47 Current Ratio1.44 Quick Ratio1.19 Price-To-Earnings Trailing P/E Ratio20.85 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$15.99 billion Price / Sales2.05 Cash Flow$2.0236 per share Price / Cash10.39 Book Value$11.61 per share Price / Book1.81 Profitability EPS (Most Recent Fiscal Year)N/A Net Income$1.69 billion Net Margins10.40% Return on Equity8.29% Return on Assets3.96% Miscellaneous EmployeesN/A Outstanding Shares1,562,360,000Market Cap$32,583.02 Takeda Pharmaceutical (OTCMKTS:TKPYY) Frequently Asked Questions What is Takeda Pharmaceutical's stock symbol? Takeda Pharmaceutical trades on the OTCMKTS under the ticker symbol "TKPYY." How were Takeda Pharmaceutical's earnings last quarter? Takeda Pharmaceutical Co Ltd (OTCMKTS:TKPYY) issued its quarterly earnings results on Monday, May, 14th. The company reported ($0.32) EPS for the quarter. The business earned $3.70 billion during the quarter. Takeda Pharmaceutical had a return on equity of 8.29% and a net margin of 10.40%. View Takeda Pharmaceutical's Earnings History. When is Takeda Pharmaceutical's next earnings date? Takeda Pharmaceutical is scheduled to release their next quarterly earnings announcement on Friday, July, 27th 2018. View Earnings Estimates for Takeda Pharmaceutical. What is the consensus analysts' recommendation for Takeda Pharmaceutical? 0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Takeda Pharmaceutical in the last year. There are currently for the stock, resulting in a consensus recommendation of "N/A." Who are some of Takeda Pharmaceutical's key competitors? Some companies that are related to Takeda Pharmaceutical include Novo Nordisk A/S (NVO), Abbott Laboratories (ABT), Sanofi (SNY), GlaxoSmithKline (GSK), Eli Lilly And Co (LLY), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Celgene (CELG), Allergan (AGN), Shire (SHPG), Vertex Pharmaceuticals (VRTX), Zoetis (ZTS), Regeneron Pharmaceuticals (REGN) and ASTELLAS PHARMA/ADR (ALPMY). Who are Takeda Pharmaceutical's key executives? Takeda Pharmaceutical's management team includes the folowing people: Mr. Christophe Weber, Presidednt, CEO & Representative Director (Age 52)Mr. Andrew S. Plump M.D., Ph.D., Chief Medical & Scientific Officer and DirectorDr. Seigo Izumo M.D., Chair of Management BoardMr. Costa Saroukos, Chief Financial OfficerMr. Haruhiko Hirate, Member of Management Board and Corp. Communications & Public Affairs Officer Has Takeda Pharmaceutical been receiving favorable news coverage? Media coverage about TKPYY stock has been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern scores the sentiment of media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Takeda Pharmaceutical earned a daily sentiment score of 0.16 on Accern's scale. They also assigned media stories about the company an impact score of 46.25 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next several days. How do I buy shares of Takeda Pharmaceutical? Shares of TKPYY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Takeda Pharmaceutical's stock price today? One share of TKPYY stock can currently be purchased for approximately $21.0250. How big of a company is Takeda Pharmaceutical? Takeda Pharmaceutical has a market capitalization of $32.58 billion and generates $15.99 billion in revenue each year. How can I contact Takeda Pharmaceutical? Takeda Pharmaceutical's mailing address is 1-1 Doshomachi 4-chome Chuo-ku, Osaka M0, 540-8645. The company can be reached via phone at 816-6204-2111 or via email at [email protected] MarketBeat Community Rating for Takeda Pharmaceutical (OTCMKTS TKPYY)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 92 (Vote Outperform)Underperform Votes: 83 (Vote Underperform)Total Votes: 175MarketBeat's community ratings are surveys of what our community members think about Takeda Pharmaceutical and other stocks. Vote "Outperform" if you believe TKPYY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TKPYY will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/20/2018 by MarketBeat.com StaffFeatured Article: What do I need to know about analyst ratings?